In a mouse model of n‐AMD, we demonstrated that simultaneously reducing the levels of VEGFR‐2 and ANG‐2 by LYTAC Plus hydrogel indeed improved the therapeutic effect compared to the control groups, as evidenced by small leakage fluorescence, reduced choroidal neovascularization (CNV) areas and width, as well as enhanced electrophysiological function of the inner retina. The gene discussed is ANGPT2; the disease is age-related macular degeneration.